Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy

Linrong Li, Armando Giuliano, Qiang Sun, Xiaojiang Cui, Yuan Yuan · 2026

Read Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy by Linrong Li, Armando Giuliano, Qiang Sun, Xiaojiang Cui, Yuan Yuan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13502141.txt.

Description

Linrong Li leads a five-author team with a 2026 review of antibody-encapsulated drugs, a proposed successor to antibody-drug conjugates in cancer therapy. Conjugates weld a poison to an antibody, but the welding is uneven: drug-to-antibody ratios vary, linkers can leak early, and production is complex. The new platform instead tucks a fixed number of drug molecules inside an antibody without a covalent bond, using a technique called single protein encapsulation. That promises exact dosing, less premature release, and simpler production.

The proof-of-concept pairs trastuzumab, a HER2-targeting antibody, with actinomycin D sealed inside it. Across cancer models with varying HER2 levels the construct killed tumours while showing a friendly toxicity profile in animals. Parallel trials of albumin-encapsulated medicines support the wider platform. The authors position the approach as a way past conjugate resistance and limits, widening which payloads and proteins can be used.

Catalog record

CREATORLinrong Li, Armando Giuliano, Qiang Sun, Xiaojiang Cui, Yuan Yuan
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE11858
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13502141

Browse the full library · About the Tower of Babel